科文斯现更名为Labcorp Drug Development

作为一家全球性公司,我们致力于为千百万人的福祉共同创新,持续为您带来更先进的医学突破。

了解详情

MV(4;11):人AML(急性髓细胞白血病)模型

Author: Erin Trachet, Sr. Scientific Advisor, Oncology / Sr. Manager, Proposal Development
Date: December 2016


急性髓细胞性白血病(AML)是骨髓造血细胞中祖细胞的恶性疾病,代表一种遗传异质性癌症。人们认为AML的发作需要活跃增殖与髓样分化缺陷的共同作用,这通常会导致染色体易位(Gilliland等人,2004)。AML的年发病率为每100,000人约1.8例,其发病率随着年龄的增长而显著增加。临床上正在研究改善AML结局的许多新型治疗策略。然而,即使治疗方法进步和早期诊断改善,大多数患者也会死于这种疾病。

In an effort to more effectively evaluate treatments preclinically, Labcorp offers a human AML model, MV(4;11) (FUW-Luc-mCherry-puro), that has been modified to include both luciferase and mCherry reporter constructs.通过荧光素酶的表达,生物发光成像(BLI)可用于纵向测量和跟踪体内疾病进展。另外,mCherry的表达可以用于活体外,以检测骨髓中是否存在肿瘤细胞。  At Labcorp we have optimized the MV(4;11) model in female NSG mice (Jackson Labs). Our ability to track disease progression with BLI makes this model a powerful tool for investigators discovering and developing novel drugs for AML by coupling traditional pharmacology endpoints such as overall survival and body weight loss with in vivo, quantitative disease progression over time.临床上,BLI已成为血液恶性肿瘤模型量化中的基础成像方式,对于药物发现过程具有不可估量的价值。

Fig 1

Contact Labcorp today for more Information on the MV(4;11) (FUW-Luc-mCherry-puro) model or one of our other hematologic malignancy models—we have dozens of cell lines!

参考资料

请注意,所有动物护理和使用均根据动物福利法规在AAALAC认可的研究中心进行,并经过IACUC协议审查和批准。

让我们开始对话

联系我们